Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [December 2016]

Product Code:
596200613
Publication Date:
December 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Breast Cancer (BC). Pfizer announces the EU approval of Ibrance (palbociclib) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic BC; Novartis announces FDA priority review for the company's marketing application seeking approval of ribociclib (LEE011) as a first-line treatment for postmenopausal women with HR+/HER2-, advanced or metastatic BC in combination with letrozole; PharmaMar reports positive results of its Phase II study of lurbinectedin (PM1183) in patients with BRCA 1/2 –associated metastatic BC.

Highlights from this event update bulletin:

  • How do KOLs react to the EU approval of Ibrance (palbociclib)?
  • How is Ibrance likely to be used in the treatment paradigm?
  • According to KOLs, what are the chances of Ibrance being used as an adjuvant therapy in the future?
  • What do KOLs think of ribociclib and what challenges will it face?
  • What are KOL opinions of the Phase II data of lurbinectedin (PM1183) in patients with BRCA 1/2 – associated metastatic BC?
  • Where could lurbinectedin be positioned in the treatment algorithm?

 




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved